Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome

Gonçalves, Flavia M.; Jacob-Ferreira, Anna L.; Gomes, Viviani; Casella-Filho, Antonio; Chagas, Antônio Carlos Palandri; Marcaccini, Andrea M.; Gerlach, Raquel Fernanda; Tanus‐Santos, José Eduardo

doi:10.1016/j.cca.2009.02.013

Cited by 85 publications

(62 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although little is known about the biological effects of MMP-8, some studies have shown elevated levels of MMP-8 in subclinical and clinical atherosclerosis [13], unstable angina [22], metabolic syndrome [12], and childhood obesity [23]. Conversely, reduced levels of MMP-8 were associated with diastolic heart failure [24].…”

Section: Discussionmentioning

confidence: 99%

“…The current study was delineated to exclude clinical conditions and pharmacotherapeutic factors, such as hypertension, diabetes, cardiovascular disease, use of statins, and smoking, that may affect the MMP and TIMP-1 levels [5,8,12,33].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, clinical studies have shown that alteration in the expression or activity of MMPs and/or TIMPs is an important mechanism underlying the pathophysiology of some cardiovascular diseases [5][6][7][8] and contributes to ventricular dysfunction [6] and atherosclerotic lesions [9]. Studies evaluating circulating levels of MMP-8 (neutrophil collagenase) in obese women without associated comorbidities have not yet been evaluated, although some studies have shown higher MMP-8 levels in subjects presenting with cardiovascular disorders [12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women

Andrade

Petruceli

Belo

et al. 2012

Clinical Biochemistry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women

Andrade

Petruceli

Belo

et al. 2012

Clinical Biochemistry

View full text Add to dashboard Cite

“…MMP9, which is released from adipose tissue (Bouloumie et al 2001), is a key enzyme involved in these processes. Higher plasma and tissue MMP9 levels are found in obese subjects (Laimer et al 2005) and patients with the metabolic syndrome (Goncalves et al 2009). In this study, the NOD1 ligand induced MMP9 gene expression and secretion of pro MMP9 from both subcutaneous and omental adipose tissues.…”

Section: Figurementioning

confidence: 99%

NOD1 expression is increased in the adipose tissue of women with gestational diabetes

Lappas¹

2014

Journal of Endocrinology

View full text Add to dashboard Cite

Maternal peripheral insulin resistance and increased inflammation are two features of pregnancies, complicated by gestational diabetes mellitus (GDM). The nucleotide-binding oligomerisation domain (NOD) intracellular molecules recognise a wide range of microbial products, as well as other intracellular danger signals, thereby initiating inflammation through activation of nuclear factor kB (NFkB). The aim of this study was to determine whether levels of NOD1 and NOD2 are increased in adipose tissue of women with GDM. The effect of NOD1 and NOD2 activation on inflammation and the insulin signalling pathway was also assessed. NOD1, but not NOD2, expression was higher in omental and subcutaneous adipose tissues obtained from women with GDM when compared with those from women with normal glucose tolerance (NGT). In both omental and subcutaneous adipose tissues from NGTand GDM women, the NOD1 ligand g-D-glutamyl-meso-diaminopimelic acid (iE-DAP) significantly induced the expression and secretion of the pro-inflammatory cytokine interleukin 6 (IL6) and chemokine IL8; COX2 (PTGS2) gene expression and subsequent prostaglandin production; the expression and secretion of the extracellular matrix remodelling enzyme matrix metalloproteinase 9 (MMP9) and the gene expression and secretion of the adhesion molecules ICAM1 and VCAM1. There was no effect of the NOD2 ligand muramyl dipeptide on any of the endpoints tested. The effects of the NOD1 ligand iE-DAP were mediated via NFkB, as the NFkB inhibitor BAY 11-7082 significantly attenuated iE-DAP-induced expression and secretion of pro-inflammatory cytokines, COX2 gene expression and subsequent prostaglandin production, MMP9 expression and secretion and ICAM1 and VCAM1 gene expression and secretion. In conclusion, the present findings describe an important role for NOD1 in the development of insulin resistance and inflammation in pregnancies complicated by GDM.

show abstract

“…12,13,[28][29][30] While there is evidence that MMPs in erectile dysfunction JJ Muniz et al patients with ED are more likely to have the vascular alterations commonly found in cardiovascular diseases, 2,4-9 especially among diabetics, 4-6,10,11 our findings showed similar net MMP-2 and MMP-9 activities in ED patients and in healthy controls, thus suggesting that these enzymes may not be involved in ED. Importantly, MMPs levels were carefully assessed by two independent, different techniques in the present study, thus minimizing the probability of analytical limitations.…”

Section: Discussionmentioning

confidence: 41%

Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction

et al. 2011

View full text Add to dashboard Cite

Erectile dysfunction (ED) may reflect vascular alterations associated with imbalanced matrix metalloproteinases (MMPs) activities. However, no previous study has compared MMPs levels in ED patients with those found in healthy subjects. We measured the circulating MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in ED patients, with or without diabetes mellitus (DM), and in healthy controls. We studied 28 healthy men (control group), 35 men with ED (ED group), and 33 men with ED and DM (ED/DM group). MMP-2, MMP-9, TIMP-1 and TIMP-2 plasma levels were measured by enzyme-linked immunosorbent assay and zymography. We found no differences in MMP-9 levels (P40.05) among groups. However, while patients in the ED group had similar TIMP-1 levels compared with those found in the control group, we found higher TIMP-1 levels and lower MMP-9/ TIMP-1 ratios in the ED/DM group compared with controls (Po0.05). While both groups of patients (ED and ED/DM) had slightly lower MMP-2 levels compared with controls (Po0.05), we found no differences in TIMP-2 levels among the study groups (P40.05), and no differences in MMP-2/TIMP-2 ratios (P40.05). We found evidence indicating lack of significant alterations in circulating net MMP-9 and MMP-2 activities in patients with ED, and lower net MMP-9 activity in diabetic patients with ED.

show abstract

Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome

Cited by 85 publications

References 44 publications

Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women

Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women

NOD1 expression is increased in the adipose tissue of women with gestational diabetes

Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction

Contact Info

Product

Resources

About